They're confident, as are all biotechs who believe in their pipeline. Correct, no one can be sure. IR is not saying they can take it to market for these indications, but that they can take it without partners. The latter was the point.
I have seen less confident Biotechs, but ofcourse it does not say anything. One thing though. They have locked data which is great.
The experts looking at Anavex data would know in one glance if the trial has failed. If Anavex would know the trial failed we will know within a couple of business days as required by law. They are taking weeks so therefore I take it the trial succeed. In what way good enough for P3 extension or good enough for AP remains to be seen.
Market Data 
Markets 
AI
